Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 10/20 | 0.52 |
| ▸ | CA1 | P00915 | 9/20 | 0.52 |
| ▸ | CA2 | P00918 | 9/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30194239 | 0.86 | PTGS2 (0.69) | CA9CA1CA2PTGS2PTGS1 | |
| SCHEMBL3103871 | 0.73 | CA1 (0.50) | CA9CA1CA2PTGS2PTGS1 | |
| SCHEMBL14292307 | 0.73 | CA1 (0.50) | CA9CA1CA2PTGS2PTGS1 | |
| SCHEMBL20042423 | 0.73 | CA9 (0.47) | CA9CA1CA2PTGS2PTGS1 | |
| SCHEMBL20042435 | 0.73 | PTGS2 (0.58) | CA9CA1CA2PTGS2PTGS1 | |
| SCHEMBL3107422 | 0.73 | CA1 (0.56) | CA9CA1CA2PTGS2PTGS1 | |
| SCHEMBL20042422 | 0.72 | PTGS2 (0.48) | CA9CA1CA2PTGS2PTGS1 | |
| SCHEMBL5698738 | 0.71 | PTGS2 (0.65) | CA9CA1CA2PTGS2PTGS1 | |
| SCHEMBL20042412 | 0.70 | PTGS2 (0.57) | CA9CA1CA2PTGS2PTGS1 | |
| SCHEMBL20042430 | 0.69 | CA9 (0.47) | CA9CA1CA2PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390026-B1 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RES FOUNDATION INC (US) | 2010-05-05 | — | — | EP | claimed |
| EP-1146789-B1 | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/NEU | CORNELL RES FOUNDATION INC (US) | 2009-03-18 | — | — | EP | claimed |
| EP-1390026-B1 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RES FOUNDATION INC (US) | 2010-05-05 | — | — | EP | disclosed |
| EP-1146789-B1 | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/NEU | CORNELL RES FOUNDATION INC (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1039914-A4 | CYCLOOXYGENASE-2 INHIBITION | CORNELL RES FOUNDATION INC (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1146789-A4 | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/NEU | CORNELL RES FOUNDATION INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7041694-B1 | Cyclooxygenase-2 inhibition | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-6486203-B1 | Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors | CORNELL RESEARCH FOUNDATION, INC. | 2002-11-26 | — | — | US | disclosed |
| US-6403630-B1 | ADMINISTERING A CYCLOOXYGENASE-2 (COX-2) INHIBITOR ALONE OR IN COMBINATION WITH HERCEPTIN? ANTIBODY; USED TO TREAT BREAST CANCER | CORNELL RESEARCH FOUNDATION, INC. | 2002-06-11 | — | — | US | disclosed |
| EP-1146789-A1 | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/NEU | CORNELL RESEARCH FOUNDATION, INC. (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1039914-A1 | CYCLOOXYGENASE-2 INHIBITION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-2000044225-A1 | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/neu | CORNELL RESEARCH FOUNDATION, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-1999030721-A1 | CYCLOOXYGENASE-2 INHIBITION | CORNELL RESEARCH FOUNDATION, INC. (US) | 1999-06-24 | — | — | WO | disclosed |